Literature DB >> 24002649

Matrix metalloproteinases and their pathological upregulation in multiple sclerosis: an overview.

Mohammad A Javaid1, Mohamed-Nur Abdallah, Ahad S Ahmed, Zeeshan Sheikh.   

Abstract

Matrix metalloproteinases (MMPs) are a family of extracellular proteases associated with extracellular matrix remodeling. They are involved in many physiological and reparative processes. MMPs can break down all extracellular constituents; therefore, their expression is very tightly regulated and their abnormal activity or over production has been linked to many diseases including multiple sclerosis (MS) which is a leading cause of non-traumatic disability in young adults in North America. Recently many studies, both in animals and humans, have been conducted to better elucidate the underlying causes, mechanisms and pathophysiology of MS. In this review, we discuss the potential role of pathological upregulation of MMPs in MS and future challenges which if properly addressed might help in development of potential cure for this disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24002649     DOI: 10.1007/s13760-013-0239-x

Source DB:  PubMed          Journal:  Acta Neurol Belg        ISSN: 0300-9009            Impact factor:   2.396


  14 in total

Review 1.  Genetic and Molecular Biology of Multiple Sclerosis Among Iranian Patients: An Overview.

Authors:  Meysam Moghbeli
Journal:  Cell Mol Neurobiol       Date:  2019-09-03       Impact factor: 5.046

2.  Second Generation Triple-Helical Peptide Inhibitors of Matrix Metalloproteinases.

Authors:  Manishabrata Bhowmick; Dorota Tokmina-Roszyk; Lillian Onwuha-Ekpete; Kelli Harmon; Trista Robichaud; Rita Fuerst; Roma Stawikowska; Bjorn Steffensen; William Roush; Hector R Wong; Gregg B Fields
Journal:  J Med Chem       Date:  2017-04-19       Impact factor: 7.446

Review 3.  Matrix metalloproteinase contribution in management of cancer proliferation, metastasis and drug targeting.

Authors:  Nabil M Abdel-Hamid; Shimaa A Abass
Journal:  Mol Biol Rep       Date:  2021-08-11       Impact factor: 2.316

4.  Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in the hippocampus of lithium-pilocarpine-induced acute epileptic rats.

Authors:  Ding Wan; Lu Yang; Jia Ren; Haiyue Huang; Chen Zhang; Le Chen; Xueyao Su; Qi Huang; Jianguo Niu; Tao Sun; Peng Wang
Journal:  Mol Biol Rep       Date:  2022-06-17       Impact factor: 2.742

Review 5.  Regulation and Function of Matrix Metalloproteinase-13 in Cancer Progression and Metastasis.

Authors:  Shun Li; David Mark Pritchard; Lu-Gang Yu
Journal:  Cancers (Basel)       Date:  2022-07-03       Impact factor: 6.575

6.  Leukocyte Gene Expression and Plasma Concentration in Multiple Sclerosis: Alteration of Transforming Growth Factor-βs, Claudin-11, and Matrix Metalloproteinase-2.

Authors:  Gholamreza Hassanzadeh; Samaneh Hosseini Quchani; Mohammad Ali Sahraian; Farid Abolhassani; Mohammad Ali Sadighi Gilani; Masoomeh Dehghan Tarzjani; Fatemeh Atoof
Journal:  Cell Mol Neurobiol       Date:  2016-01-14       Impact factor: 5.046

Review 7.  Can tetracyclines ensure help in multiple sclerosis immunotherapy?

Authors:  Pedro Víctor-Carvalho; Rodolfo Thome; Catarina Rapôso
Journal:  J Clin Transl Res       Date:  2021-02-03

Review 8.  Candidate prognostic markers in breast cancer: focus on extracellular proteases and their inhibitors.

Authors:  David M Roy; Logan A Walsh
Journal:  Breast Cancer (Dove Med Press)       Date:  2014-07-03

9.  Lack of association of matrix metalloproteinase-3 gene polymorphism with susceptibility to rheumatoid arthritis: a meta-analysis.

Authors:  Zhitao Feng; Guochao He; Zhuanghong Chen; Zhengzhi Wu; Juan Li
Journal:  BMC Musculoskelet Disord       Date:  2014-11-18       Impact factor: 2.362

10.  Comparison of the Effects of Matrix Metalloproteinase Inhibitors on TNF-α Release from Activated Microglia and TNF-α Converting Enzyme Activity.

Authors:  Eun-Jung Lee; Pyong-Gon Moon; Moon-Chang Baek; Hee-Sun Kim
Journal:  Biomol Ther (Seoul)       Date:  2014-09-30       Impact factor: 4.634

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.